Applied Therapeutics (APLT) Equity Average (2023 - 2025)
Historic Equity Average for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to $8.4 million.
- Applied Therapeutics' Equity Average fell 7844.13% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year decrease of 7844.13%. This contributed to the annual value of $19.9 million for FY2024, which is N/A changed from last year.
- Applied Therapeutics' Equity Average amounted to $8.4 million in Q3 2025, which was down 7844.13% from $27.1 million recorded in Q2 2025.
- In the past 5 years, Applied Therapeutics' Equity Average registered a high of $69.8 million during Q2 2024, and its lowest value of -$14.1 million during Q4 2023.
- Moreover, its 3-year median value for Equity Average was $26.1 million (2024), whereas its average is $22.2 million.
- Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 176174.16% in 2024, then tumbled by 7844.13% in 2025.
- Quarter analysis of 3 years shows Applied Therapeutics' Equity Average stood at -$14.1 million in 2023, then skyrocketed by 323.12% to $31.4 million in 2024, then tumbled by 73.17% to $8.4 million in 2025.
- Its last three reported values are $8.4 million in Q3 2025, $27.1 million for Q2 2025, and $46.8 million during Q1 2025.